Review Article

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

Claudio Fozza and Maurizio Longinotti

Institute of Hematology, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy

Correspondence should be addressed to Claudio Fozza, cfozza@uniss.it

Received 15 July 2010; Accepted 18 February 2011

The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of patients. In recent years, among the more traditional therapeutic options, rituximab, an anti-CD20 monoclonal antibody, has shown interesting results in the treatment of primary AHA. Although this drug has been frequently used for AHA in patients with CLL, much less data are available on its use in NHL patients. However, considering that the main pathogenetic mechanism of AHA in course of lymphoproliferative disorders seems to be an antibody production directly or indirectly mediated by the neoplastic clone, this monoclonal antibody represents an ideal therapeutic approach. In this paper we will briefly describe some biological and clinical features of NHL-patients with AHA. We will then analyze some studies focusing on rituximab in primary AHA, finally reviewing the available literature on the use of this drug in NHL related AHA.

1. Autoimmune Hemolytic Anemia in Non–Hodgkin Lymphomas

The association between lymphomagenesis and autoimmunity is a well-known scenario mainly derived from reports describing both patients and mouse strains in which autoimmune manifestations and lymphoproliferative disorders coexisted [1]. On the other hand in recent years population-based studies have specifically shown that several autoimmune disorders are associated with an increased risk in developing non-Hodgkin lymphomas (NHL) [2, 3]. Some factors have been specifically advocated as possible explanations for this association, such as chronic immune stimulation, immunomodulating drugs, and common genetic or environmental variables. Lymphomagenesis and autoimmunity could be pathogenetically put together by considering that both of them result from the impairment of the physiologic mechanisms which should control lymphoid cell growth and differentiation [4].

Autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia [5], has been described also in a small proportion of NHL, patients, ranging from 3 to 6% in different cohorts [6, 7]. Besides several anecdotal reports [8], clinical and prognostic features of patients with AHA have been investigated in a large cohort of NHL patients. In this study 16 subjects (3%) with AHA have been selected among 517 NHL patients. Ten patients had B-cell NHL, 5 T-cell NHL and 1 poorly differentiated NHL while follicular lymphoma was the most represented subtype, having being diagnosed in 5 subjects. While looking at different subtypes of AHA warm and cold antibodies were identified in 13 and 3 patients respectively. Patients with AHA showed a trend towards a worse response rate to antilymphoma treatments and were apparently characterized by a reduced overall survival, although one may speculate that this finding represents just a surrogate of the worse prognosis correlated to both T-cell phenotype and paraproteinemia. Finally, in most patients a discrepancy among time to response of NHL and AHA was observed, thus suggesting...
possible different pathways mediating response to treatment [6].

In another series evaluating 370 NHL patients AHA was detected in 23 patients (6.2%), 19 with warm-type and 4 with cold-type antibodies. This report then focused on the 4 cases with cold agglutinin disease (CAD), showing then that all of them were having low-grade NHL and had monoclonal IgM gammopathy. In 3 of them both NHL and AHA showed a good response to chlorambucil plus prednisone [7].

A somehow specular point of view has been recently offered by the above-mentioned case population study on patients with autoimmune manifestations, which showed that even AHA, although much less than other autoimmune diseases, is associated with a 2.6-fold increase in NHL risk. This association is even more evident among subjects with long AHA duration and is stronger for B-cell NHL, especially for the diffuse large B-cell lymphoma subtype [2]. Another report has also suggested that AHA could be preferentially associated with other NHL subtypes, such as marginal zone NHL and T-cell lymphomas [3].

2. Rituximab in Primary Autoimmune Hemolytic Anemia

In recent years, among the more traditional therapeutic options, such as steroids and other immunomodulating drugs, also monoclonal antibodies have become available for the treatment of AHA. Apart from limited experiences with alemtuzumab [9], rituximab has shown the most interesting results. This monoclonal antibody is directed against the CD20 antigen expressed on B-lymphocytes and is widely used in the treatment of lymphoproliferative disorders. More in details, it has been nowadays incorporated in the first line treatment of both indolent [10] and aggressive NHL [11], having offered in both conditions a marked improvement in terms of response rates and overall survival.

In the preliminary studies on the use of rituximab on AHA, after the first report on a child with AHA associated to pure red cell aplasia successfully treated with rituximab and intravenous immunoglobulins [12], 13 out of 15 children with warm antibody AHA showed responses to rituximab [13]. On the other hand, it was also highlighted as in 4 patients with Evan’s syndrome either immune thrombocytopenia or AHA only responded, but not both [14].

Besides several case reports, in recent years three manuscripts have focused on larger patient cohorts. D’Arena and colleagues described the use of rituximab in warm-type idiopathic AHA. All patients were refractory to steroids and/or immunosuppressive drugs and all were given weekly rituximab 375 mg/m² for four consecutive weeks. An increase in hemoglobin levels was observed in all cases, with a mean increment of 3.3 g/dL. At a mean followup of 604 days, 8 patients were still in complete remission and 3 in partial remission [15]. Recently, the effects of 68 courses of rituximab in 53 Belgian patients with AHA were reported. All patients were given rituximab after failing at least one previous line of treatment, including splenectomy in 19% of them. Overall response rates were 79%, with a median followup since first rituximab administration of 15 months. Progression-free survival at 1 and 2 years was 72% and 56% respectively [16]. The efficacy and safety of rituximab was also evaluated in a retrospective study including 27 adults with warm antibody AHA refractory to several previous lines of therapy. Overall, 8 patients achieved a complete response and 17 a partial response. After a mean followup of 21 months, 5 patients relapsed and 3 of them were successfully retreated with rituximab [17].

3. Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

The rational of using rituximab in NHL patients experiencing AHA is dual. First of all, as above mentioned, this drug has been demonstrated to play a relevant role in the treatment of primary AHA, having been widely tested in patients refractory to previous line of treatment [12–17]. Moreover, as the main pathogenetic mechanism of NHL related AHA seems to be an antibody production directly or indirectly mediated by the neoplastic clone [18, 19], exploiting a well-demonstrated antilymphoma treatment is undoubtedly an intriguing strategy.

Ten years ago, rituximab has been frequently employed in AHA occurring in chronic lymphocytic leukemia (CLL) [30], and its use has been recently incorporated in the guidelines from the International Workshop on CLL [31]. The experience in using rituximab in NHL patients with AHA is much less robust and so far, besides some reports on patients with concomitant CAD and lymphoproliferative disorders [32–34], ten single cases have been reported between 1998 and 2009 [20–29], as shown in Table 1. The more frequent histological patterns are lymphoplasymacytic [22–24] and marginal zone NHL [20, 25–27, 29], described in 4 and 5 cases respectively. A patient with splenic T-cell angioimmunoblastic NHL has been also described, representing the only reported case in which rituximab was unsuccessful [28]. In 6 out of 10 cases, cold agglutinins were detected while mixed and warm autoantibodies were present in 1 and 3 cases, respectively. All the patients were refractory to at least one previous treatment and 5 out of the 9 patients who then responded to rituximab had previously received three or more lines of treatment. In most cases rituximab was administered at a dose of 375 mg/m² weekly for four weeks, sometimes in association with steroids or other medications. In all the reported case, with the exception of the splenic T-cell angioimmunoblastic NHL, a complete remission of AHA occurred within the first month from the first rituximab administration and responses were usually long lasting. As most of these case reports describe patients with indolent NHL, in which disease eradication is usually not a primary goal of the treatment, the degree of response of the lymphoproliferative disorders to rituximab was usually not reported. Interestingly a patient with small lymphocyte NHL who developed severe hemolytic anaemia due to posttransfusionical alloimmunization, was very recently reported to respond to a rituximab-based immunochemotherapy [35]. The efficacy of rituximab was
also reported in a case in which both an aggressive form of multicentric Castleman disease and AHA responded [36].

As above mentioned, some reports evaluated the efficacy of rituximab in patients with CAD, some of which had concomitant lymphoproliferative disorders. Berentsen and colleagues reported about the use of rituximab in the context of a population-based clinical study of 86 patients with primary chronic CAD, 76% of which had concomitant NHL. Thirty-three patients had lymphoplasmacytic lymphoma, 5 marginal zone lymphoma, 4 small lymphocytic B-cell lymphoma or, CLL and 8 undefined clonal lymphocytosis. In such a context rituximab was the only successful approach, showing response rates around 60%, apparently nondifferent among patients suffering or not from NHL [32]. The same group reported on 37 courses of rituximab monotherapy administered within a prospective trial to 27 patients with primary CAD, 19 of which with concomitant NHL. Fourteen of the 27 patients responded to the first course of rituximab showing 1 complete and 13 partial remissions, according to the response criteria defined in the study. Eight patients relapsed and were retreated with rituximab, in some patients associated with interferon, resulting in 5 partial remissions. On the whole, responses were achieved after 20 of 37 courses of rituximab. Median time to response was 1.5 months, while median increase in hemoglobin level was 4.0 g/L. The median response duration was 11 months and all but one responders observed for more than 12 months relapsed [33]. Slightly lower response rates have been reported in a prospective study of 20 patients with chronic CAD, 7 of which had lymphoproliferative disorders [34].

In conclusion, although it should be noted that patients unsuccessfully treated with rituximab are much less likely to be reported, the analysis of the available literature suggests that this monoclonal antibody represents a valid therapeutic option in the treatment of AHA in NHL patients. Keeping in mind that a high proportion of patients relapse after an initial response to rituximab, it remains to be determined if this drug may play a role even in the maintenance. Considering both the pathogenetic mechanisms underlying AHA in NHL patients as well as the poor response rates offered by other therapeutic alternatives, we conclude that rituximab can be considered a valid strategy in NHL patients with steroid refractory AHA as well as a possible option for first-line treatment in selected cases.

Conflict of Interests

The authors report no conflict of interests.

References

[1] R. C. Mellors, “Autoimmune disease in NZB-B1 mice. II. Autoimmunity and malignant lymphoma,” Blood, vol. 27, no. 4, pp. 435–448, 1966.

[2] E. Ekström Smedby, C. M. Vajdic, M. Falster et al., “Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium,” Blood, vol. 111, no. 8, pp. 4029–4038, 2008.

[3] L. A. Anderson, S. Gadalla, L. M. Morton et al., “Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies,” International Journal of Cancer, vol. 125, no. 2, pp. 398–405, 2009.

[4] C. C. Goodnow, “Multistep pathogenesis of autoimmune disease,” Cell, vol. 130, no. 1, pp. 25–35, 2007.

[5] T. J. Hamblin, “Autoimmune complications of chronic lymphocytic leukemia,” Seminars in Oncology, vol. 33, no. 2, pp. 230–239, 2006.

[6] S. Sallah, G. Sigounas, P. Vos, J. Y. Wan, and N. P. Nguyen, “Autoimmune hemolytic anemia in patients with non-Hodgkin’s lymphoma: characteristics and significance,” Annals of Oncology, vol. 11, no. 12, pp. 1571–1577, 2000.

[7] T. Economidou, N. Stathakis, M. Constantiniou, E. Papageorgiou, C. Anastassiou, and S. Raptis, “Cold agglutinin disease in non-Hodgkin’s lymphoma,” European Journal of Haematology, vol. 55, no. 1, pp. 69–71, 1995.

[8] H. E. Eve and S. A. J. Rule, “Autoimmune haemolytic anaemia associated with mantle cell lymphoma,” International Journal of Hematology, vol. 91, no. 2, pp. 322–325, 2010.

Table 1: Reported cases of non-Hodgkin lymphoma-associated autoimmune hemolytic anemia treated with rituximab.

| First author and year of publication | NHL subtype | Antibodies | Response to rituximab | Previous treatments |
|-------------------------------------|-------------|------------|-----------------------|---------------------|
| Lee and Kueck 1998 [20]             | Marginal zone | Cold       | Yes                   | Steroids, cyclophosphamide, plasma exchange |
| Bauduer 2001 [21]                   | Lymphoplasmacytic | Cold       | Yes                   | Steroids, cyclophosphamide, cyclosporine, plasma exchange |
| Cohen et al. 2001 [22]              | Lymphoplasmacytic | Cold       | Yes                   | Steroids |
| Layios et al. 2001 [23]             | Lymphoplasmacytic | Cold       | Yes                   | Steroids, cyclophosphamide, plasma exchange, vincristine |
| Mori et al. 2002 [24]               | Lymphoplasmacytic | Cold       | Yes                   | Steroids, splenectomy, chop |
| Paydas et al. 2003 [25]             | Marginal zone | Warm       | Yes                   | Steroids |
| Petit et al. 2003 [26]              | Marginal zone | Cold       | Yes                   | Steroids, chlorambucil |
| Fabbri et al. 2006 [27]             | Marginal zone | Warm       | Yes                   | Steroids, splenectomy, cvp |
| Win et al. 2007 [28]                | Splenic T-cell angioimmunoblastic | Mixed     | No                    | Steroids, intravenous Immunoglobin, chemotherapy |
| Fozza et al. 2009 [29]              | Marginal zone | Warm       | Yes                   | Steroids |

Abbreviations: CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/prednisolone); CVP (cyclophosphamide, vincristine, prednisone/ prednisolone); NHL (non-Hodgkin lymphoma).
[9] A. Osterborg, C. Karlsson, and J. Lundin, “Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia,” Current Hematologic Malignancy Reports, vol. 4, no. 1, pp. 47–53, 2009.

[10] M. J. Overman, L. Feng, B. Pro et al., “The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma,” Annals of Oncology, vol. 19, no. 3, pp. 553–559, 2008.

[11] K. Fu, D. D. Weisenburger, W. W. L. Choi et al., “Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4587–4594, 2008.

[12] M. Zecca, P. De Stefano, B. Nobili, and F. Locatelli, “Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia,” Blood, vol. 97, no. 12, pp. 3995–3997, 2001.

[13] P. Quartier, B. Brethon, P. Philippet, J. Landman-Parker, F. Le Deist, and A. Fischer, “Treatment of childhood autoimmune haemolytic anaemia with rituximab,” The Lancet, vol. 358, no. 9292, pp. 1511–1513, 2001.

[14] T. D. Shanafelt, H. L. Madueme, R. C. Wolf, and A. Tefferi, “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome,” Mayo Clinic Proceedings, vol. 78, no. 11, pp. 1340–1346, 2003.

[15] G. D’Arena, C. Califano, M. Annunziata et al., “Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients,” European Journal of Haematology, vol. 79, no. 1, pp. 53–58, 2007.

[16] D. Dierickx, G. Verhoef, A. van Hoof et al., “Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study,” Journal of Internal Medicine, vol. 266, no. 5, pp. 484–491, 2009.

[17] G. Bussonne, E. Ribeiro, A. Dechartres et al., “Efficacy and safety of rituximab in adults’ warm antibody autoimmune haemolytic anaemia: retrospective analysis of 27 cases,” American Journal of Hematology, vol. 84, no. 3, pp. 153–157, 2009.

[18] L. Borche, A. Lim, J. L. Binet, and G. Dighiero, “Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies,” Blood, vol. 76, no. 3, pp. 562–569, 1990.

[19] G. Dighiero and L. Borche, “Evidence that the B lymphocyte proliferating in B-CLL and in other B-CELL malignancies is frequently committed to production of natural autoantibodies,” Nouvelle Revue Francaise d’Hematologie, vol. 32, no. 3, pp. 323–326, 1990.

[20] E. J. Lee and B. Kueck, “Rituxan in the treatment of cold agglutinin disease,” Blood, vol. 92, no. 9, pp. 3490–3491, 1998.

[21] F. Bauduer, “Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin’s lymphoma,” British Journal of Haematology, vol. 112, no. 4, pp. 1085–1086, 2001.

[22] Y. Cohen, A. Polliack, O. Zelig, and A. Goldfarb, “Monotherapy with Rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma,” Leukemia and Lymphoma, vol. 42, no. 6, pp. 1405–1408, 2001.

[23] N. Layios, E. van den Neste, E. Jost, V. Deneyes, J. M. Scheiff, and A. Ferrant, “Remission of severe cold agglutinin disease after rituximab therapy,” Leukemia, vol. 15, no. 1, pp. 187–188, 2001.

[24] A. Mori, I. I. Tamaru, H. Sumi, and H. Kondo, “Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy,” European Journal of Haematology, vol. 68, no. 4, pp. 243–246, 2002.

[25] S. Paydas, S. Yavuz, U. Disel, B. Sahin, and M. Ergin, “Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase,” Leukemia and Lymphoma, vol. 44, no. 12, pp. 2165–2166, 2003.

[26] J. Petit, M. Clavo, A. F. de Sevilla, E. Gonzalez-Barca, E. Domingo-Domenech, and A. Graiena, “Refractory cold agglutinin-immunohaemolytic anaemia associated to marginal zone lymphoma responding to rituximab,” Hematology Journal, vol. 4, no. 6, pp. 450–451, 2003.

[27] A. Fabbi, A. Gozzetti, S. Lazzi et al., “Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia,” Clinical Lymphoma and Myeloma, vol. 6, no. 6, pp. 496–499, 2006.

[28] N. Win, D. Tiwari, V. L. Keevil, M. Needs, and A. Lakhani, “Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T cell angioimmunoblastic non-Hodgkins lymphoma,” Hematology, vol. 12, no. 2, pp. 159–162, 2007.

[29] C. Fozza, A. Galleu, M. G. Careddu et al., “Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma,” Annals of Hematology, vol. 89, no. 1, pp. 113–114, 2010.

[30] G. Seipel, A. Böhme, S. Koschmieder, and D. Hoelzer, “Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome,” Annals of Hematology, vol. 80, no. 3, pp. 170–173, 2001.

[31] M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008.

[32] S. Berentsen, E. Ulvestad, R. Langholm et al., “Primary chronic cold agglutinin disease: a population based clinical study of 86 patients,” Haematologica, vol. 91, no. 4, pp. 460–466, 2006.

[33] S. Berentsen, E. Ulvestad, B. T. Gjertsen et al., “Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients,” Blood, vol. 103, no. 8, pp. 2925–2928, 2004.

[34] C. Schöllkopf, L. Kjeldsen, O. W. Bjerrum et al., “Effect of rituximab on primary cold agglutinin disease: a prospective study of 20 patients,” Leukemia and Lymphoma, vol. 47, no. 2, pp. 253–260, 2006.

[35] E. Sigler, L. Shvidel, V. Yahalom, A. Berrebi, and M. Shtalrid, “Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion—severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab,” Transfusion, vol. 49, no. 7, pp. 1370–1374, 2009.

[36] E. M. Ocío, F. M. Sanchez-Guijo, M. Diez-Campeol et al., “Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena,” American Journal of Hematology, vol. 78, no. 4, pp. 302–305, 2005.